临床试验/NCT07594093

NCT07594093招募中1 期

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of REGN20934 in Adult Participants With Overweight or Obesity

Regeneron Pharmaceuticals1 个研究点分布在 1 个国家目标入组 90 人开始时间: 2026年6月29日最近更新: 2026年7月7日

干预措施

试验速览

阶段: 1 期
状态: 招募中
发起方: Regeneron Pharmaceuticals
入组人数: 90
试验地点: 1

研究概览研究设计入排标准研究组 & 干预措施研究者研究点记录与标识符相似试验

研究概览

简要总结

This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity.

The study is looking at:

What side effects REGN20934 might cause
How much REGN20934 is in the blood at different times
If the body makes antibodies to REGN20934

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Sequential
主要目的: Treatment
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

Sponsor unblinded

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•Has a Body Mass Index (BMI) 25 to 35 kg/m^2
•Females must be of non-childbearing potential

排除标准

•A self-reported change of body weight >5 kg within approximately 90 days of visit 2
•History of type 1 or type 2 diabetes
•History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease, as defined in the protocol
•Note: Other protocol defined inclusion/exclusion criteria apply

研究组 & 干预措施

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

REGN20934

Experimental

干预措施: REGN20934 (Drug)

研究者

发起方

Regeneron Pharmaceuticals

申办方类型

Industry

责任方

Sponsor

研究点 (1)

Loading locations...

相似试验

招募中

1 期

A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy AdultsHealthy Volunteer

NCT07526116Regeneron Pharmaceuticals88

招募中

1 期

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic DermatitisHealthy VolunteerAtopic Dermatitis

NCT07527923Regeneron Pharmaceuticals144

招募中

2 期

Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

NCT07318597Regeneron Pharmaceuticals99

尚未招募

1 期

A Study to Evaluate the Safety and Tolerability of Intravenous Stemis™ in Elderly Subjects With Mild to Moderate Frailty Syndrome

NCT07462819Ji Yan Biomedical Co., Ltd.12

招募中

3 期

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation

NCT07626411Regeneron Pharmaceuticals15,364